Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications.

Kocks JWH, Harrison T, Bell JP, Rignall A, Khezrian M, Usmani OS

Open source

DOI
10.1007/s41030-026-00362-1
Published
2026 Jun
Container
Pulmonary therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s41030-026-00362-1,
  title = {Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications.},
  author = {Kocks JWH and Harrison T and Bell JP and Rignall A and Khezrian M and Usmani OS},
  year = {2026},
  journal = {Pulmonary therapy},
  doi = {10.1007/s41030-026-00362-1},
  url = {https://doi.org/10.1007/s41030-026-00362-1}
}

RIS

TY  - JOUR
TI  - Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications.
AU  - Kocks JWH
AU  - Harrison T
AU  - Bell JP
AU  - Rignall A
AU  - Khezrian M
AU  - Usmani OS
PY  - 2026
JO  - Pulmonary therapy
DO  - 10.1007/s41030-026-00362-1
UR  - https://doi.org/10.1007/s41030-026-00362-1
ER  - 

APA

JWH, K., T, H., JP, B., A, R., M, K., & OS, U. (2026). Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications.. Pulmonary therapy. https://doi.org/10.1007/s41030-026-00362-1

Source records